REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its second quarter 2025 financial results and recent operational developments. The company will host a webcast that can be accessed through a registration link.
Analysts can participate in the Q&A session by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 9571992. A replay will be available on REGENXBIO's investor website approximately two hours after the call concludes. Participants are encouraged to join 15 minutes before the start time.
REGENXBIO (Nasdaq: RGNX) ha programmato una conference call per giovedì 7 agosto 2025, alle 8:00 ET per discutere i risultati finanziari del secondo trimestre 2025 e gli ultimi sviluppi operativi. La società trasmetterà un webcast accessibile tramite un link di registrazione.
Gli analisti potranno partecipare alla sessione di domande e risposte chiamando il numero (646) 307-1963 (nazionale) o (800) 715-9871 (internazionale) con il codice di accesso 9571992. Una registrazione sarà disponibile sul sito degli investitori di REGENXBIO circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell’inizio.
REGENXBIO (Nasdaq: RGNX) ha programado una conferencia telefónica para el jueves 7 de agosto de 2025 a las 8:00 a.m. ET para discutir los resultados financieros del segundo trimestre de 2025 y los desarrollos operativos recientes. La compañía ofrecerá una transmisión web accesible mediante un enlace de registro.
Los analistas pueden participar en la sesión de preguntas y respuestas llamando al (646) 307-1963 (nacional) o al (800) 715-9871 (internacional) con el código 9571992. Una repetición estará disponible en el sitio web para inversores de REGENXBIO aproximadamente dos horas después de que finalice la llamada. Se recomienda a los participantes unirse 15 minutos antes del inicio.
REGENXBIO (나스닥: RGNX)는 2025년 8월 7일 목요일 오전 8시 ET에 2025년 2분기 재무 실적 및 최근 운영 현황에 대해 논의하는 컨퍼런스 콜을 예정하고 있습니다. 회사는 등록 링크를 통해 접속할 수 있는 웹캐스트를 진행할 예정입니다.
애널리스트들은 (646) 307-1963 (국내) 또는 (800) 715-9871 (국제) 번호로 접속하여 패스코드 9571992를 입력해 Q&A 세션에 참여할 수 있습니다. 콜 종료 약 2시간 후 REGENXBIO 투자자 웹사이트에서 다시 듣기가 제공될 예정입니다. 참가자들은 시작 15분 전에 접속하는 것이 권장됩니다.
REGENXBIO (Nasdaq : RGNX) a programmé une conférence téléphonique pour le jeudi 7 août 2025 à 8h00 ET afin de discuter des résultats financiers du deuxième trimestre 2025 et des développements opérationnels récents. La société organisera un webcast accessible via un lien d'inscription.
Les analystes peuvent participer à la session de questions-réponses en appelant le (646) 307-1963 (national) ou le (800) 715-9871 (international) avec le code d'accès 9571992. Une rediffusion sera disponible sur le site des investisseurs de REGENXBIO environ deux heures après la fin de l'appel. Il est conseillé aux participants de se connecter 15 minutes avant le début.
REGENXBIO (Nasdaq: RGNX) hat eine Telefonkonferenz für Donnerstag, den 7. August 2025, um 8:00 Uhr ET angesetzt, um die Finanzergebnisse des zweiten Quartals 2025 und aktuelle betriebliche Entwicklungen zu besprechen. Das Unternehmen wird einen Webcast anbieten, der über einen Registrierungslink zugänglich ist.
Analysten können an der Fragerunde teilnehmen, indem sie (646) 307-1963 (national) oder (800) 715-9871 (international) mit dem Zugangscode 9571992 anrufen. Eine Aufzeichnung wird etwa zwei Stunden nach Ende der Telefonkonferenz auf der Investorenseite von REGENXBIO verfügbar sein. Teilnehmer werden gebeten, 15 Minuten vor Beginn beizutreten.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 9571992. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-quarter-2025-financial-results-and-operational-highlights-302518467.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) reporting Q2 2025 earnings?
How can investors access REGENXBIO's Q2 2025 earnings call?
Will there be a replay of REGENXBIO's Q2 2025 earnings call?
What time should participants join REGENXBIO's Q2 2025 earnings call?
